If you've been getting compounded semaglutide from a telehealth platform or compounding pharmacy, there's a reasonable chance your provider hasn't told you something important: the legal basis that made your prescription possible has, for most patients, already expired.
The FDA removed semaglutide from its drug shortage list in early 2025. The window for most compounding pharmacies to legally produce it closed on April 22, 2025 for patient-specific (503A) pharmacies, and May 22, 2025 for bulk outsourcing facilities (503B). That was over a year ago.
A meaningful number of pharmacies are still shipping compounded semaglutide. Telehealth platforms are still prescribing it. Patients are still receiving and injecting it — often without knowing the regulatory basis that permitted it was removed months ago.
This article covers what actually happened, what it means if you're currently using compounded semaglutide, what the difference between semaglutide and tirzepatide looks like from a regulatory standpoint right now, what safety concerns are specific to compounded GLP-1s (not branded versions), and what legitimate options actually exist.
Harm reduction note: This is informational content, not medical or legal advice. GLP-1 medications are approved drugs with established clinical evidence — the concerns here are not about the molecule but about supply chain integrity, regulatory compliance, and concentration safety in compounded formats. If you're making decisions about your medication, your prescriber should be part of that conversation.
How This Started: The Shortage That Made Compounding Possible
Compounded versions of brand-name drugs occupy a specific legal space. Under 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of commercially available drugs if those drugs appear on the FDA's shortage list.
Semaglutide — the active ingredient in Ozempic (diabetes) and Wegovy (obesity) — was on the shortage list for years, driven by explosive demand that the manufacturer (Novo Nordisk) couldn't keep pace with. During that shortage period, compounding pharmacies could legally produce semaglutide, and they did, at massive scale. Telehealth platforms built entire business models around it. Millions of patients who couldn't get or afford branded Ozempic/Wegovy got access to compounded versions at a fraction of the cost.
This was the legal framework: shortage → compounding permitted → affordable access → millions of patients.
Then the shortage ended.
What the Shortage Removal Actually Did
The FDA's determination that Wegovy had sufficient supply, finalized in early 2025, removed semaglutide from the shortage list. This triggered a clock.
- 503A pharmacies (traditional compounding pharmacies that fill patient-specific prescriptions): required to stop producing compounded semaglutide by April 22, 2025
- 503B outsourcing facilities (bulk manufacturers that supply prescriptions across states without patient-specific orders): required to stop by May 22, 2025
This wasn't a sudden announcement — there were court challenges, lobbying from compounding pharmacy associations, and a grace period that the FDA granted before the deadlines. But the deadlines passed.
What this means in plain language: If you received a refill of compounded semaglutide after May 22, 2025, the pharmacy that filled it was operating outside the FDA's guidance on when compounding is permitted under the shortage exemption. That doesn't mean you committed a crime by receiving and using it — the regulatory exposure is primarily on the pharmacy side. But it does mean the supply chain you're relying on may be operating in violation of FDA guidance, which has implications for enforcement risk and, more practically, quality control.
This is the fact most people using compounded semaglutide have not been told.
The B12 Loophole (And Why It's Closing)
When the shortage ended and the compounding deadlines hit, some pharmacies found what they believed was a workaround: add another ingredient.
Compounding pharmacies can produce "combination drug products" — formulations that combine multiple compounds in a single preparation — without the same shortage-based restrictions. The theory: semaglutide + Vitamin B12 (methylcobalamin or cyanocobalamin) isn't the same thing as semaglutide alone, so the combination might be permissible even after the shortage exemption expires.
This became widespread quickly. "Semaglutide with B12" appeared on telehealth platforms and from pharmacies as the post-deadline alternative. Some platforms rebranded seamlessly — patients who had been receiving plain compounded semaglutide were switched to semaglutide-B12 without being told why.
The FDA's response: The agency has explicitly stated that this approach does not comply with the law. Adding a trace amount of another compound to circumvent shortage-based compounding restrictions is not a legitimate use of the combination product provisions. The FDA has sent warning letters to compounding pharmacies operating under this framing and has made clear that semaglutide, with or without B12 or other additives, falls under the same post-shortage restrictions.
Courts have been involved. Compounding pharmacy trade associations filed lawsuits challenging FDA's authority to enforce the shortage deadlines. Some courts have issued temporary injunctions in specific jurisdictions. The legal picture has been genuinely complicated, with different rules potentially applying depending on where the pharmacy is located and which court's ruling applies to it.
The practical takeaway: "semaglutide with B12" from a compounding pharmacy is operating under legal arguments that the FDA has rejected, that are currently being litigated, and that vary by jurisdiction. It is not a clearly lawful alternative to branded semaglutide. Patients receiving it are not necessarily at legal risk, but the pharmacy they're using may be.
The Safety Concern Nobody Talks About: Concentration
This is the "wow, I didn't know that" part for GLP-1 users.
Branded Wegovy and Ozempic are delivered via pre-filled auto-injector pens. The dose is fixed — you set it, you inject it, and the device controls exactly how much you get. The concentrations are standardized. The formulations have been through clinical manufacturing validation.
Compounded semaglutide typically comes as a multi-dose vial with lyophilized (freeze-dried) powder that you reconstitute yourself, or as a pre-mixed liquid. You draw a volume using a syringe and inject subcutaneously.
This creates a concentration math problem that has caused documented harm.
Compounded semaglutide vials vary in concentration — commonly 2mg/mL, 4mg/mL, 5mg/mL, or even higher — and the instructions for how much to draw vary by vendor. If a patient is used to drawing 0.5mL from a 2mg/mL vial (getting 1mg of semaglutide) and switches to a 4mg/mL vial without adjusting, they inject 2mg without realizing it.
Semaglutide overdose causes severe nausea, vomiting, and hypoglycemia. The FDA has received adverse event reports attributable to dosing errors with compounded semaglutide, including hospitalizations. At least one death has been reported in connection with a GLP-1 compounded medication error, though causality is complex.
The COA connection: The same verification problem that exists for research peptides exists here in a different form. For compounded semaglutide, the questions to ask are:
- What is the exact concentration of my vial (mg/mL)?
- Does the concentration in my vial match what the label says?
- Has the pharmacy provided any testing documentation confirming concentration and purity?
If you're unclear on any of these, that's a problem worth resolving before your next injection. The COA verification framework in the first article of this series applies directly here — ask for mass spec, ask for HPLC purity, ask for a lot-specific document. Most regulated compounding pharmacies will have this; pharmacies operating in the post-shortage gray zone may not.
Tirzepatide: A Different Situation
Tirzepatide is the active ingredient in Mounjaro (diabetes) and Zepbound (obesity), made by Eli Lilly. It's a GIP/GLP-1 dual agonist — mechanistically different from semaglutide, though the clinical weight-loss and blood glucose effects are similar.
Tirzepatide's shortage status removal timeline was different from semaglutide's:
- The FDA removed tirzepatide from the shortage list in late 2024, but with a different enforcement posture
- Litigation by compounding pharmacy associations specifically targeting tirzepatide's shortage determination was more extensive
- Courts issued temporary injunctions that applied to tirzepatide in ways they didn't for semaglutide
- As of mid-2025, some compounding of tirzepatide remained in a genuine legal gray zone, actively contested in federal courts
This is meaningfully different from semaglutide. The semaglutide window is largely closed. The tirzepatide window is contested — there is active litigation, court orders, and regulatory uncertainty that makes the situation genuinely ambiguous rather than clearly resolved.
If you're using compounded tirzepatide, you're in a situation more analogous to research peptides like BPC-157 (as covered in the previous article in this series): the regulatory landscape is actively shifting, the legal basis is contested, and the outcome depends heavily on court decisions that haven't been fully settled.
What's not ambiguous: the FDA has said compounded tirzepatide should stop. Courts have partially blocked that enforcement. Pharmacies in states with favorable court orders may still be operating legally. Pharmacies elsewhere may not be.
What Options Actually Exist
Here's the honest picture of what legitimate access to semaglutide looks like now.
Branded Ozempic and Wegovy through insurance: The supply shortage that drove compounding demand is resolved. For patients with qualifying diagnoses (Type 2 diabetes for Ozempic, BMI ≥30 or ≥27 with weight-related condition for Wegovy), coverage exists through many insurance plans. The prior authorization process is cumbersome but navigable. This is the clearest legal pathway.
Novo Nordisk patient assistance programs: NovoCare (Novo Nordisk's patient assistance program) offers Wegovy for approximately $25/month for qualifying patients who don't have insurance coverage and meet income criteria. This is significantly less than list price and uses the branded, properly manufactured product. The program exists and is underutilized because pharmacies offering compounded versions never had financial incentive to mention it.
Mark Cuban's Cost Plus Drugs: As of mid-2025, Cost Plus Drugs does not offer semaglutide — the active ingredient isn't available at the generics price point because it's still patent-protected. But this is worth watching: when patents expire or if approved generics emerge (which is a future scenario, not a current one), Cost Plus would likely be a pathway.
Telehealth platforms with branded prescriptions: Several telehealth platforms (Hims/Hers pivoting post-compounding, Noom Weight, others) have moved toward branded prescription models with insurance navigation. The monthly cost is higher than compounded versions, but these prescriptions carry no regulatory ambiguity.
State-specific programs: Some states have weight-loss medication access programs or Medicaid coverage that includes GLP-1s for qualifying patients. Coverage varies dramatically by state.
The honest answer is that affordable access to semaglutide has gotten meaningfully harder since the compounding window closed. The compounded version served a real patient need. That the legal basis for it has expired doesn't mean the need went away. But the options above are the legitimate pathways that currently exist.
The Harm Reduction Summary
Here is the complete picture for someone currently using compounded semaglutide in mid-2025:
Regulatory status: The shortage-based compounding exemption expired April 22–May 22, 2025. Pharmacies producing compounded semaglutide after those dates are operating outside FDA guidance. The B12/additive approach does not resolve this — FDA has explicitly rejected it. You are not the enforcement target, but your supply chain is operating in violation of agency policy.
Tirzepatide distinction: More legally contested. Active litigation means some compounding may have court-backed legal cover depending on jurisdiction. Less clear-cut than semaglutide.
Safety concern unique to compounded GLP-1s: Concentration errors are real and documented. Know the exact mg/mL of your vial. Verify that your dose calculation accounts for the concentration. Request documentation from your pharmacy confirming the concentration was tested.
What to do:
- If you're currently using compounded semaglutide: check whether your pharmacy is a licensed 503A or 503B facility, ask for lot-specific testing documentation, and verify your concentration math before every injection
- If you want to transition to a legitimate supply: contact Novo Nordisk's NovoCare program, ask your prescriber about insurance prior authorization, or look into telehealth platforms that have shifted to branded prescriptions
- If you're evaluating tirzepatide: the situation is more fluid — worth monitoring litigation outcomes before assuming legality in your state
Tools and Resources
PeptideGuard — built for research peptides, but the harm-reduction framework for evaluating compound quality, COA documentation, and regulatory status applies directly to compounded medications. Useful for thinking through documentation questions and regulatory context when your prescriber or pharmacy can't give you a straight answer.
NovoCare Patient Assistance (novonordisk-us.com/novocare) — Novo Nordisk's official patient assistance and affordability program for Wegovy and Ozempic. Income-based qualification; $25/month program for eligible patients.
FDA MedWatch (fda.gov/safety/medwatch) — where adverse events associated with compounded medications are reported. If you experience a severe reaction to a compounded GLP-1, this is where reports go — and reviewing reported events gives you a realistic picture of what's been documented.
FDA Drug Shortage Database (accessdata.fda.gov/scripts/drugshortages) — real-time list of drugs currently designated as in shortage. Check here to verify the current status of semaglutide and tirzepatide directly from the source rather than relying on pharmacy or telehealth platform claims.
What's Next in This Series
The July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee meeting includes BPC-157 on the agenda. The PCAC outcomes — which could shift BPC-157's regulatory status for the first time — will be covered here within 48 hours of the committee's recommendations being published. If you're using BPC-157 and haven't read what that meeting means, the previous article covers the stakes.
The next article covers a question that doesn't get enough serious coverage: the stack. CJC-1295, ipamorelin, and the GH secretagogue combinations are the most commonly used peptide stacks in the community — and the harm reduction picture for those combinations is almost entirely absent from responsible sources. That's next.
This article is for harm-reduction and informational purposes only. This is not medical or legal advice. Regulatory status is subject to change — verify current status with primary sources before making decisions about your medications. If you are using a GLP-1 medication, consult your prescriber before making any changes.
